Moringa oleifera leaf extract at 300 µg/mL demonstrated selective elimination of senescent neuroblastoma cells induced by amyloid-β oligomers, while reducing inflammatory cytokines IL-8 and TNF-α. The extract targeted cells expressing senescence markers p21, p16, and γH2AX, inducing apoptosis specifically in damaged cells rather than healthy ones. This selective senolytic activity represents a significant advancement in natural therapeutics for neurodegeneration. Current synthetic senolytics like dasatinib and quercetin show promise but carry substantial side effect profiles, making natural alternatives particularly valuable. The finding aligns with emerging evidence that cellular senescence drives Alzheimer's progression through inflammatory cascades. However, this remains early-stage cell culture research using a single neuroblastoma line exposed to artificial amyloid conditions. The 300 µg/mL concentration would need careful translation to human dosing, and whether moringa's senolytic effects extend to actual brain tissue requires validation. While confirmatory rather than paradigm-shifting, this work provides compelling rationale for advancing moringa toward animal studies and eventual human trials as a potentially safer senolytic intervention.